[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100342360":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":33,"locations":43,"responsibleParty":64,"collaborators":32,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":32,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":32,"enrollmentInfo":76,"targetDuration":32,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ropivacaine Continuous Infusion Catheter","ACTIVE_COMPARATOR","Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg\u002Fkg) and maintained with 0.2% ropivacaine infusion 8 ml\u002Fhour via catheter.",[13],"Drug: Ropivacaine Continuous Infusion Catheter",{"label":15,"type":10,"description":16,"interventionNames":17},"Single dose liposomal bupivicaine","Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.",[18],"Drug: Single Dose Liposomal Bupivicaine",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg\u002Fkg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml\u002Fhr of 0.2% ropivacaine on the inpatient floor.",[9],[25],"TAP block initiated with ropivacaine bolus and infusion",{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Single Dose Liposomal Bupivicaine","TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.",[15],[31],"TAP block with liposomal bupivacaine",null,[34,39],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Ana Arias, BS","CONTACT","916-703-5456","apaarias@ucdavis.edu",{"name":40,"role":36,"phone":41,"phoneExt":32,"email":42},"Natasha Piniero, BS","916-734-5171","nspiniero@ucdavis.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University of California Davis","RECRUITING","Sacramento","California","95817","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-121.4944,38.58157,{"lat":56,"lon":55},[59,60,61],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},{"name":40,"role":36,"phone":41,"phoneExt":32,"email":42},{"name":62,"role":63,"phone":32,"phoneExt":32,"email":32},"Richard Applegate, MD","PRINCIPAL_INVESTIGATOR",{"type":65,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100342360","phase-4-tap-blocks-with-ropivacaine-continuous-infusion-catheters-vs-single-dose-liposomal-bupivicaine-after-kidney-transplant-100342360",false,"NCT03737604","TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant","Transversus Abdominis Plane (TAP) Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine: A Prospective Randomized Control Trial for Pain Control After Renal Transplant Surgery","Inclusion Criteria:\n\n* Patients ages 18 years or older\n* Renal Transplant Recipients\n\nExclusion Criteria:\n\n* Patients less than 18 years of age\n* Pregnant Women\n* Prisoners\n* Opioid Tolerant Patients taking more than 30 mg\u002Fday of oral morphine equivalent analgesia\n* Patients on Systemic anti coagulation\n* Patients unable to provide consent\n* Hypersensitivity to amide-type local anesthetic or any component of the drug formula",true,"ALL","18 Years",{"count":77,"type":78},200,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","This study is a comparison of the analgesic efficacy of transversus abdominis plane (TAP) blocks with ropivacaine bolus plus continuous ropivacaine infusion via catheters versus single shot TAP blocks with liposomal bupivacaine.",[84,85],"Transplant;Failure,Kidney","Pain, Postoperative",[87,88,89],"Transversus Abdominis Plane Block","Ropivacaine","Liposomal bupivacaine","2026-02-13",{"date":92,"type":93},"2026-02-18","ACTUAL",{"date":95,"type":93},"2018-10-04",{"date":97,"type":78},"2026-06-12",{"name":5,"class":6},1]